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Alzheimer’s disease (AD) is the most common form of
dementia in the elderly, making up between 50% and 60%
of all cases, with dementia with Lewy bodies combined
with frontotemporal dementia (FTD) making up the other
large segment (15%–25%) [1]. AD is a neurodegenerative
disease that features loss of memory and impairment of
cognitive function but is often difficult to differentiate
from other forms of dementia, especially in the early clinical
stages. Two major forms of AD have been recognized, a fa-
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AD (LOAD) variety affecting most AD patients. Although
EOAD has a genetic basis and has been closely tied to the
amyloid hypothesis [2] of the disease, LOAD has genetic
associations and probably results from a combination of
environmental factors, genetic susceptibilities, and yet to
be determined influences. Some of these environmental fac-
tors are particularly relevant to the military. The growing
military population exposed to significant stressors, espe-
cially over the last 15 years of multiple deployments, pro-
vides evidence that unique combat-related environmental
factors can influence the risk of developing AD, possibly
via shared and yet to be defined mechanisms associated
with traumatic brain injury (TBI) and posttraumatic stress
disorder (PTSD) [3].
There are clear signs that both military and civilian pop-
ulations have increasing risks of AD going forward. A recent
study by the Department of Veterans Affairs showed that
their subject groups with PTSD had double the risk ofeserved.
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severe TBI had two to four times the risk of developing AD
or other dementias as they age [5]. The increased risk of AD
conferred by TBI is a growing concern not only in the mili-
tary but also in the civilian arena, particularly as it relates to
sport-related concussive injury. TheWorld Health Organiza-
tion currently estimates that approximately 35.6 million peo-
ple are afflicted by AD worldwide. In the United States,
approximately 7 million people older than 65 years are
known to suffer from AD, and this number is expected to tri-
ple by 2050. According to the 2013 facts and figures from the
Alzheimer’s Association (AA) [6], although the number of
deaths from major diseases such as cancer and cardiovascu-
lar disease has declined in the past decade, the number of
deaths related to AD has increased 68% during the 2000 to
2010 period (Fig. 1). Major advances in treatment for the
various diseases, except AD, are reflected in these statistics,
as well as the increasing longevity of our population. In addi-
tion, the increasing numbers of AD-related deaths reflect an
augmented precision by the medical community in diag-
nosing clinical dementia and documenting the suspected
cause of demise. In an era of decreasing autopsy confirma-
tion of clinical dementia diagnoses, the absolute numbers
may be uncertain, but the trend is irrefutable.
The social and psychological burden associated with car-
ing for those afflicted with AD remains difficult to quantify.
The health-care costs associated with managing these indi-
viduals are staggering and threaten to bankrupt not only
the United States but also the rest of the world economies
if left unchecked. In the United States alone, AD-related
health-care costs were estimated in 2010 to surpass $170
billion and projected to exceed $1 trillion by 2050 [7].
Such a societal need and cost have driven significant
research funding by governments, pharmaceutical com-
panies, and private organizations toward developing suc-
cessful remedies for AD. Unfortunately, the progressive
course of this illness has yet to be significantly impacted
by any of the developed therapeutic strategies to date. Pro-Fig. 1. Bar chart representation of estimated percent changes in reported deaths
related to specific diseases during the 2000 to 2010 period, based on World
Health Organization statistics [6]. HIV, human immunodeficiency virus.jected delays in disease onset by as little as 5 years, resulting
from a successful therapeutic strategy, have the potential to
reduce the Medicare costs of AD nearly in half [8].
Patient selection for therapeutic AD trials has been pred-
icated on the presence of symptomatic disease, either mild
cognitive impairment (MCI) [9] or AD [10], based on
recently updated clinical criteria. There has not been a clear
distinction, unfortunately, in the development and testing of
therapeutic agents targeting the treatment of EOAD versus
LOAD, despite their distinct etiologies and clinical trajec-
tories and relatively rare occurrence of the former. Although
certain transgenic animal models approach pathogenic
modeling of human EOAD [11,12], no such models exist
for LOAD, which would need to replicate both etiologic
genetic predisposition and environmental factors.
Although military blast-related TBI is associated with
certain neuropathologic features similar to those of chronic
traumatic encephalopathy [13], including overexpression
of phosphorylated tau (p-tau), these changes remain distinct
from those associated with LOAD [14]. Although drugs
directed toward attenuating the amyloidogenic process
may be supported in cases of EOAD [15], similar clinico-
pathologic evidence is lacking for LOAD. Unfortunately,
the bulk of drugs tested so far in the clinic have been in
LOAD (MCI or AD) subjects and focused toward modu-
lating amyloid pathophysiology. Resultant efficacy mea-
sures in these investigations have either been unimpressive
or lacking in late-stage clinical trials for the various thera-
peutic agents tested to date and with significant associated
cost of these failures. An upcoming therapeutic clinical trial
for genetically defined EOAD [16], the Alzheimer’s Preven-
tion Initiative, may have a higher likelihood of efficacy
because of the improved definition of the afflicted pathobio-
logic networks in the proposed subjects and treatment during
the preclinical stage of the disease. Unfortunately, EOAD
subjects comprise only a small portion of the afflicted pop-
ulation, and therapeutic success in this group of subjects
may not necessarily generalize to those with LOAD.
As a result of this lack of therapeutic efficacy in LOAD,
many geriatricians and neurodegenerative disease specialists
have postulated that the neural substrate in this disorder may
not be responsive to currently used pharmacologic agents
after the onset of clinical symptoms. Although possible
that the right therapeutic agent has not been tested yet, the
wide variety of drugs examined make this less likely. For
many, the lack of therapeutic success may result from the de-
cision to initiate treatment trials during the clinical stages of
AD. The lack of efficacy documented within these well-
financed and well-developed drug trials certainly supports
this clinical observation. As a result, over the last 5 years,
there has been a push to better understand the preclinical
(asymptomatic) stages of AD and consider secondary pre-
vention studies [8], where the neural substrate may remain
more receptive to therapeutic intervention.
The preclinical stages of AD are based on documentation
of the temporal neuropathologic changes in clinically
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are believed to include the clinical manifestations of AD
after progressing beyond a “tipping point” of compensatory
mechanisms [17,18]. Enhanced insights into the molecular
neuropathology and neurochemistry have led investigators
to devise methods for assessing the pathobiologic
signatures of the various preclinical and clinical AD
stages. Most biomarkers have been used to support the
clinical diagnosis of AD, correlating findings in vivo with
postmortem brain specimens and differentiating
neuropathologic observations from those in normal
individuals. Few, if any, have successfully defined
preclinical signatures that accurately predict those destined
to phenoconvert from normal to impaired cognition during
the asymptomatic stages of AD.
Despite major advances in clinical chemistry, brain imag-
ing, and genomic capabilities, there remains a need for the
definition of accurate biosignatures for preclinical AD,
which will differentiate subjects without risk of progression
to dementia from those at risk for developing prodromal or
actual AD. Such biomarkers are urgently needed. Until accu-
rate preclinical indicators are defined and validated, the
promise of disease-modifying therapeutic strategies for
AD will remain elusive.
In this review, we update the reader on the current state of
biomarker development for preclinical AD, concentrating on
the status and continuing issues associated with cerebrospi-
nal fluid (CSF), neuroimaging, and peripheral blood meth-
odologies. We will stress the importance of consistently
and strictly defining the clinical assessments correlated
with the various putative preclinical biosignatures. We will
make the case for consistency in clinical and biomarker
data collection for all AD biomarker types, to allow more
thorough and rapid comparisons between investigations.
Such uniformity in data collection may provide rapid insight
into novel biosignatures that may advance preclinical defini-
tion and treatment options for AD and further the hope of
modifying disease outcome.2. The recognition of preclinical AD
The major impetus behind the preclinical AD effort was
the emerging realization that decades of concerted work in
understanding the pathophysiology and mechanisms had
led to no viable cures or disease-modifying therapeutics.
Symptomatic treatments are available but with less than
desirable efficacy. In addition, animal models of AD, even
the highly touted triple transgenic mouse models, do not
demonstrate the same pathology or the behavioral phenotype
of the human disease. Finally, there is a greater realization
that those forms that have strong genetic components
(EOAD) may not represent most cases (LOAD), where there
may be less genetic and more epigenetic contributions.
There is also increasing recognition that AD can present
with various behavioral manifestations, beyond the most
common primary amnestic variant, including those princi-pally involving language, visuospatial [19], and behavioral
cognitive spheres. Thus, with the prodromal diversity of
AD and variable genetic contributions, it is overwhelmingly
likely that AD may represent more than nosologic entities,
with multiple etiological substrates that include amyloid pla-
ques and neurofibrillary tangles (NFTs).
In 2011, the National Institute on Aging (NIA) and the
AA convened an international panel of scientists and thought
leaders in dementia to discuss diagnostic guidelines for
detection and diagnosis of AD. The panel’s mandate was
to review and consolidate the past several decades of work
on AD and come to a consensus on a set of criteria for diag-
nosis of AD. Additionally, the requisite next steps in
research strategy were proposed, which will lead to effective
treatments, a cure, and/or primary and secondary prevention
of AD. The new guidelines that emerged from the meeting
added to and expanded on the existing diagnostic guidelines
for dementia due to AD [10], MCI due to AD [9], and neuro-
pathologic findings at autopsy that support a diagnosis of AD
[20]. The fourth and perhaps most provocative guideline put
forth by the group outlines the preclinical stage of AD [8].
This new guideline recognizes that the disease process, as
evidenced by the underlying neuropathology of AD, likely
begins years to decades before clinical symptoms such as
memory loss manifest. The guideline stops short of advo-
cating for diagnosis of preclinical AD or setting out diag-
nostic criteria but instead sets out subsequent steps for a
research agenda that focuses on biomarker development
for preclinical AD. The agenda was proposed to motivate re-
searchers to develop longitudinal studies examining the rela-
tionships between specific biomarkers, initially focusing on
amyloid-b (Ab) pathology, and cognitive decline. The pro-
posed framework was to facilitate future clinical trials of
disease-modifying agents in the preclinical stages of AD,
whose efficacy will be monitored via biomarker progression
and/or the emergence of the clinical prodrome.
The NIA-AA guideline on preclinical AD adds a major
theoretical context to our understanding of AD by recog-
nizing that the pathobiology begins years to decades before
the clinical picture is apparent. The asymptomatic (preclin-
ical) state put forth by the working group consists of three
distinct stages, representing the presumed evolution of AD
pathobiology. Stage 1 is characterized by asymptomatic
amyloidosis that may begin as early as young adulthood
and evolve slowly through midlife and into old age. This
Ab pathology within the central nervous system (CNS)
may be evident by increased positron emission tomography
(PET) Ab ligand binding and low CSFAb1-42 levels. Stage 2
represents an evolution of stage 1 to include not only
amyloidosis but also early neurodegeneration as evidenced
by (1) neuronal dysfunction based on neuroimaging, such
as PET or magnetic resonance imaging (MRI), (2) cellular
indicators of neurodegeneration, including high CSF tau or
p-tau concentrations, or (3) structural brain changes based
on MRI, including cortical thinning and hippocampal atro-
phy (HA). Finally, stage 3 is evidenced by amyloidosis,
Fig. 2. A schematic representation of changes in cognitive function with
advancing age, in the presence of Alzheimer’s disease (AD). Cognitive
function varies from the intact state to the impaired state. The cognitive
threshold (small dashed black horizontal line) separates the two states of
cognitive function and determines the onset of clinical progression (or phe-
noconversion) from preclinical to prodromal mild cognitive impairment
(MCI) and eventual AD.Within the intact state, above the clinical threshold,
are the preclinical stages described in the text (stages 1, 2, and 3). The cogni-
tive range for an individual (area between large dashed black curves) deter-
mines the significant perceived variability of behavior and function during
both intact and impaired states and increases with advancing age. The under-
lying physiology (gray line within cognitive range) is based on the underly-
ing pathobiologic process and impacted by one or more precipitating events,
eventually leading to AD. The underlying physiology fluctuates in a limited
stuttering fashion, becoming progressively skewed toward cognitive impair-
ment with advancing age, especially after crossing the cognitive threshold.
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denced by mild change from baseline cognitive function
and poor performance on more challenging cognitive tests.
The cognitive deficits in stage 3 fall short of frank impair-
ment, loosely defined as between 1 and 1.5 standard devia-
tions below the mean, and do not significantly affect
functional capacities such as typical activities of daily living.
Thus, stage 3 cognitive deficits do not meet criteria for MCI.
In summary, the three preclinical stages are, by definition,
without the cognitive impairment that defines MCI and the
cognitive and functional impairments that define AD.
Recognition of a preclinical state is a major advancement
in our thinking about AD because the preclinical state repre-
sents a window of opportunity for timely disease-modifying
intervention or secondary prevention. Insights from under-
standing the early disease process manifest within the pre-
clinical state may also lead to primary prevention
strategies that may significantly alter the prevalence of
AD. Analogies to other chronic diseases such as heart dis-
ease and diabetes can be made. In cardiovascular disease,
for example, hypertension may be present for years before
a positive stress test or cardiac catheterization indicates the
presence of coronary artery disease. It is clear that in most
preclinical cardiac patients, identification and management
of hypertension can prevent or at least significantly delay
the emergence of symptoms. In a similar fashion, the recog-
nition of a preclinical AD state now requires a valid and reli-
able biomarker to help define the disease stage and to
monitor progression of the underlying pathobiology. We
do not currently have the equivalent of a blood pressure
sphygmomanometer to detect or monitor preclinical AD.
The need for such valid and accurate biomarkers and the
means to measure them remains urgent.
The notion of a preclinical AD state provides a hierarchy
for early pathology that is thought to proceed in a nearly
linear fashion from asymptomatic amyloidosis to neurode-
generation, to presenting with appreciable cognitive deficits
(see Fig. 2). We must be careful not to consider this hierar-
chy as suggesting that the pathologic process necessarily
produces cumulative effects. That is, the amyloidosis of
stage 1 is not necessarily more evident in stage 2 or 3, and
the neuronal degeneration in stage 2 is not necessarily
greater in stage 3. This lack of clearly incremental pathology
allows for the possibility that a transient pathophysiology
may exist, whose manifestations may or may not return to
normal or near normal during the proximate period(s) to
clinical disease. That is, the underlying pathobiology may
present in a more punctuated and transient fashion within
the preclinical state and may not represent a long slow accu-
mulation of pathology. Significant environmental factors
(e.g., combat-related TBI) could participate in influencing
these pathobiologic fluctuations. For example, a blast-
related TBI may be associated with time-limited upregula-
tion of inflammatory pathways, which may act to precipitate
a biological cascade that results in amyloid deposition,
similar to what occurs in early AD. For biomarker discovery,this means that an optimal biosignature for one stage of
preclinical disease may not be best for other stages. This is
an important point when considering the use of a single
biomarker to predict an at-risk population or monitor
disease-modifying consequences of an agent. A single
biomarker may not be sensitive to the underlying pathology
at multiple stages of the preclinical disease.
Another important consideration for preclinical
biomarker development is that the cognitive state may lag
significantly behind the underlying pathophysiologic
changes. This is likely to impact the sensitivity of a bio-
signature for cognitive change. The behavioral and func-
tional (cognitive) range is also likely to be coarse and
nonlinear, compared with the underlying physiology (see
Fig. 2). The cognitive decline related to the pathophysiologic
alterations occurring during the preclinical stages, however,
finally reaches a threshold level in which manifestations of
clinical MCI or AD become evident. Thereafter, progression
of cognitive and pathophysiologic decline is certain.
In the absence of valid and reliable biomarkers, neuropsy-
chological testing remains the most accurate, standardized,
and widely used premortem screening method to determine
clinical MCI or AD [9,21]. Unfortunately, current
approaches to neuropsychological assessment are likely to
be less informative in the preclinical state as, by definition,
cognition is expected to be normal or near normal during
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from these assessments demand specificity of the cognitive
data, and there are numerous factors such as perceptual
deficits [22], mood disorders [23], and other systemic illness
[24] that can confound behavioral output in older adults.
Cognitive assessment is typically applied to detect deviation
from a hypothesized or empirically derived “norm.”However,
the boundaries of “normal” are not always clear and are also
often poorly operationalized in research. There is little stan-
dardization, for example, on what constitutes impairment in
cognitive research studies. Does impairment mean 1, 1.5, or
2.0 standard deviation(s) below the mean? Which normative
data are used to compare and what covariates need to be
considered (age, education, and sex) are also important issues
that lack a standard in the field. Furthermore, few studies
rigorously apply cognitive inclusion and exclusion criteria
for their normal control (NC) groups. There are also no spe-
cific guidelines related to the time of day (or year) that longi-
tudinal evaluations are carried out and whether patients are
assessed while fasting or not or before receiving any of their
medications. The inconsistent use of these operationalized
criteria in clinical studies creates major problems for interpre-
tation of intrinsic results and greatly confounds comparison of
results from one study with another.
Exactly when does an individual transition from no
cognitive deficits in preclinical stage 2 to subtle cognitive
deficits that characterize stage 3? This becomes a more prob-
lematic issue as we drive the limits of resolution for what our
cognitive testing can provide. Precision of our cognitive
measurements will need to be improved possibly through
the use of computerized adaptive cognitive assessments.
Such methods will allow for higher resolution information
to be gathered and hopefully allow for more accurate defini-
tion of preclinical transition. In the short term, however,
traditional cognitive assessment will most certainly play
an ongoing and important role in the confirmation of a diag-
nosis in which cognitive impairment (MCI) and cognitive
and functional impairment (AD) are required. The need for
minimally invasive, clinically useful, and accurate bio-
markers of preclinical AD, therefore, has never been greater.
3. Current clinical biomarkers for AD
3.1. Cerebrospinal fluid
Sampling CSF is the least invasive direct method for as-
sessing pathologic alterations occurring within the CNS. Not
only bathing the superficial portions of the brain, spinal cord,
and portions of the cranial and spinal nerves, CSF also com-
municates directly with the cerebral ventricles and extracel-
lular fluid of these structures. As such, many believe that
CSF provides an optimal source of various biomarkers for
diverse pathobiologic events occurring within the CNS,
including AD [25]. The most consistent AD correlates
within CSF have been related to concentrations of a proteo-
lytic fragment of the amyloid precursor protein, Ab1-42, in
addition to total tau (t-tau) and p-tau levels [26–28].Diagnostic accuracy of CSF biomarkers continues to
be defined but has usually been assessed in cross-sectional
studies that typically compare results from asymptomatic sub-
jects and those cognitively impaired (see Table 1) [29–32].
Although Table 1 is not an exhaustive review, it underscores
the difficulty for individual and combined CSF biomarkers
to accurately differentiate even between NCs and those with
AD. From additional CSF analyses, an “AD signature” has
been proposed, featuring low levels of Ab(Ab1-42 or Ab1-42/
Ab1-40 ratio) and elevated quantities of t-tau and p-tau
[25,28,33]. Differences in tau phosphorylation epitopes have
been used to define stages of NFT development within the
CNS in AD [34], documented in preclinical and clinical
neuropathologic stages [35]. Specifically, elevated levels of
p-tau S262 (serine 262) or p-tau T181 (threonine 181) are
noted in earlier stages of NFT development, whereas p-tau
S396 accumulates in later Braak stages when tau accumula-
tions are extracellular [34]. The combination of threeCSFbio-
markers has been effective in differentiatingNC subjects from
thosewith symptomatic disease. The primary role of CSF sig-
natures has been to help confirm suspected clinical diagnosis
of AD. Serial CSF correlations within longitudinal preclinical
to clinical AD studies are lacking, however, primarily due to
difficulty justifying this relatively risky and invasive approach
in asymptomatic individuals.
Despite reports of relatively low associatedmorbidity with
CSF collections via lumbar puncture [36,37], subjects are
exposed to special risks with this approach, ranging from
spinal headache and local back or radiating leg pains to
meningitis, epidural abscess, subdural hematoma, and death
[38–41]. Significant clinical skill of the lumbar puncturist
(MD, physician assistant, certified registered nurse
anesthetist, or certified registered nurse practitioner) is
required, as well as the use of a sterile technique, to
minimize morbidity associated with accessing lumbar CSF
[42]. Additionally, low CSF pressure/volume states [43,44],
are prevalent in the elderly, predispose these subjects to
unsuccessful taps (sometimes .20% of the time) [45] and
to higher risk of other sequelae.3.2. Neuroimaging
The regional and sequential pathophysiological brain al-
terations associated with AD are uniquely assessed through
neuroimaging methods. The minimally invasive nature of
MRI, PET, and single-photon emission computed tomogra-
phy (SPECT) scanning protocols allows regional interroga-
tion of the CNS, with the development of rich anatomic,
chemical, and physiological data sets that can be followed
temporally within individuals. Such capabilities have pro-
vided AD investigators with excellent tools for assessing
transitions from the preclinical to the clinical stages of the
illness. With some of the earliest substrate changes in AD
thought to occur at the synaptic level within the earliest
affected regions [46,47], neuroimaging has the capability
to provide a premortem assessment of the altered
Table 1
Accuracy of cerebrospinal fluid biomarkers in selected AD studies
Comparison groups* Clinical determinants Biomarkers
Reported biomarker accuracy
(Sens %/Spec %/Accu %) Reference
AD vs. NC MMSE t-tau 55–100/86–94/NA Multiple refs. reviewed in [29]
p-tau1811231 88/97/NA
p-tau2311235 53/100/NA
p-tau199 94/80/NA
p-tau231 85/97/NA
p-tau181 44/94/NA
Ab1-42 85/84/NA
Abx-42 64–85/82–91/NA
ADy vs. NC MMSE1 t-tau 69.6/92.3/80.6 [30]
ADAS-cog (11) Ab1-42 96.4/76.9/87.0
p-tau181 67.9/73.1/70.4
t-tau/Ab1-42 85.7/84.6/85.2
p-tau181/Ab1-42 91.1/71.2/81.5
LRTAA model 98.2/79.5/89.9
MCI vs. AD MMSE1 Combined 83/88/NA [31]
MCI vs. NC Others Ab1-42, p-tau, t-tau
AD vs. NC MMSE1 Combined 85/80–95/NA [32]
Others Ab1-42, p-tau, t-tau
Abbreviations: AD, Alzheimer’s disease; Sens %, sensitivity (%); Spec %, specificity (%); Accu %, accuracy (%); NC, normal control; MMSE, Mini-Mental
Status Examination; t-tau, total tau; NA, not available; Ab1-42, amyloid-b 1-42 peptide; Abx-42, amyloid b variable peptide; ADAS-Cog (11), Alzheimer’s Dis-
ease Assessment Scale-cognitive subscale 11; p-tau181, phosphorylated tau at amino acid 181 (or 199, 231, or 235); p-tau181/Ab1-42, ratio of p-tau181 to Ab1-42; t-
tau/Ab1-42, ratio of t-tau to Ab1-42.
NOTE. LRTAA model5 Ab1-421 t-tau1 APOE ε4(1)1 APOE ε4(2). Others include ADAS-Cog (11), Consortium to Establish a Registry for Alzheimer’s
Disease Assessment Scale-Cognitive Subscale, Wechsler Adult Intelligence Scale-Revised, National Institute for Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria, Trail Making Test, verbal fluency test, learning trials, delayed recall tests,
and clock drawing.
*Comparison groups featured in cross-sectional studies.
yAutopsy-diagnosed AD.
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alterations and the eventual diffuse neuropathology of the
later disease stages. In the following sections, benefits and
limitations of the major neuroimaging modalities currently
used in the study of AD subjects will be presented.
Although the time commitment and discomfort involved
with most neuroimaging investigations stress the limits of
many participating subjects, especially the elderly and
demented, cost and need of technical expertise remains the
major hurdle preventing their widespread use in clinicalmed-
icine. Cost comparisons of neuroimaging with other
biomarker methods will be covered in a separate section of
this review. Clearly, imaging technologies (MRI and PET)
require major structural facilities for regulatory compliant
operation, which adds to their economic burden, separate
from the expensive imaging technology hardware and soft-
ware. Digital imaging data collected are massive because
of the ever-increasing sophistication of the acquisition tools.
Such rich data sets require significant computing capabilities,
networking, and storage solutions to properly assess and
compare. Neuroimaging is a labor-intensive option, often
requiring several full-time skilled technicians to work with
the radiologists and scientists in properly managing the sub-
jects being scanned and effectively collecting data. In addi-
tion, physicians and scientists expend tremendous effort in
post hoc data analyses, typically along with a team of bioin-
formatics and biostatistical experts. For specialized PETimaging related toAD, costly radioligands are required, often
needing a local or on-site cyclotron for their development,
along with the specialized technical, engineering, chemical,
and physics expertise required for effective radiopharmaceu-
tical production and safe operation.
The capability of the neuroimaging modalities continues
to improve, and their role in defining the preclinical state of
AD is evolving. Like other biomarkers, accuracy of diag-
nosis is critical to their continued clinical utility and poten-
tial use as part of novel investigative strategies (see Table 2)
[48–67]. In the following sections, specific strengths and
weaknesses of the current technologies are reviewed.
Because of their minimally invasive nature and sensitivity
to the earliest changes within the brain substrate, many of
the following neuroimaging methods have been promoted
as being able to identify “leveraged cohorts” of individuals
with an elevated risk of developing clinical AD in the
short term [68]. This notion is yet to be realized, but many
are hopeful that some of the novel techniques recently devel-
oped will provide breakthroughs in AD and other diseases.
3.2.1. Structural MRI
Structural MRI (sMRI) continues to lead the commonly
used neuroimaging modalities in the clinic for investigating
clinical complaints referable to the CNS. Offering a variety
of analytical options that continue to expand with improved
hardware and software, sMRI is optimal for investigating
Table 2
Accuracy of neuroimaging biomarkers in selected AD studies
Method used (groups) Biomarker
Reported biomarker accuracy
(Sens %/Spec %/AUC) Reference
sMRI
MCI vs. AD Hippocampal and entorhinal volumes ADNI set: 80/56/0.74 [48]
QD set: 80–90/68/0.82 [48]
AD vs. NC OPLS modeling 86.1/90.4/0.95 [49]
fMRI
AD vs. NC DMN 73.3–86.7/75–93.7/NA [50]
DAN 85.7–100/81.2–100/NA [50]
VAN ,70–73.3/,70–81.2/NA [50]
PET
CX (AD vs. NC) 18FDG 90–100/85–100/NA [51–54]
Long. (MCI vs. AD1) 18FDG 44–78/81–83/NA [55,56]
Post* (AD vs. non-AD) 18FDG 84–96.7/73–85.7/NA [57–60]
AD vs. NC 11C-PiB 100/85/NA [61]
AD vs. NC 18F-flutemetamol 93/93/NA [62]
AD vs. NC 18F-florbetaben 80/91/NA [63]
SPECT
AD vs. DLB 99mTc-exametazime 81/88/0.87 [64]
AD vs. FTD 99mTc-HMPAO 45–95/67–100/0.85 [65]
AD vs. NC 99mTc-HMPAO 43–100/63–100/91 [65]
1H-MRS
AD vs. NC mI/NAA or NAA/mI 57–90/73–95/NA [66]
PSEN1 vs. NCy 1H-MRS 98/77.4/0.88 [67]
Abbreviations: AD, Alzheimer’s disease; Sens %, sensitivity (%); Spec %, specificity (%); AUC, area under the curve; sMRI, structural magnetic resonance
imaging; MCI, mild cognitive impairment; ADNI set, patient set from Alzheimer’s Disease Neuroimaging Initiative; QD set, patient set from the Questionable
dementia study; NC, normal control; OPLS, orthogonal projection to latent structures; fMRI, functional magnetic resonance imaging; DMN, default mode
network; NA, not available; DAN, dorsal attention network; VAN, ventral attention network; PET, positron emission tomography; CX, cross-sectional study;
Long., longitudinal study; 18FDG, fluorine-18 fluorodeoxyglucose; 11C-PiB, carbon-11 Pittsburgh compound B; AD1, AD with mixed diagnoses; SPECT,
single-photon emission computed tomography; DLB, dementia of Lewy body type; FTD, frontotemporal dementia; HMPAO, hexamethylpropyleneamine
oxime; 1H-MRS, proton magnetic resonance spectroscopy; PSEN1, normal asymptomatic carriers of E280A mutation.
NOTE. Non-AD includes progressive supranuclear palsy, vascular dementia, Parkinson’s disease, frontotemporal dementia, DLB, or mixed.
*Cohort postmortem.
yNormal non-E280A carriers.
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disease. Enhanced processor speeds and software capabil-
ities allow acquisition times of less than 15 minutes for
routine structural details on most 1.5- or 3-Tesla (T) ma-
chines. The high-resolution capabilities of modern sMRI
technology allow neuroimaging correlates in vivo of the pre-
viously described postmortem neuropathologic changes
noted in preclinical AD stages [35], including parahippo-
campal, hippocampal, and amygdalar atrophies. HA has
the strongest association with the diagnosis of AD and has
been incorporated into the Dubois criteria [69] and the
NIA-AA criteria [10] for AD. Generalized atrophic progres-
sion, as measured on sMRI, is also accepted as an individual
biomarker for the transition fromMCI to AD [70]. Although
manual segmentation of the hippocampal volume to deter-
mine HA remains the standard, problems with too much
variability in measurements and difficulty with reproduc-
ibility of results have prompted the neuroimaging commu-
nity to develop automated segmentation algorithms [71].
Automating the volumetric assessments helps limit vari-
ability and enhances reproducibility of results and will
augment sMRI’s utility in clinical decision making and
patient selection for clinical trials. As noted in Table 2,however, accuracy provided by sMRI alone, in most cases,
has failed to reach the threshold of clinical utility [48], typi-
cally requiring a more complex and multimodal assessment
to reach significant sensitivity and specificity [49].
Beyond the use of HA assessments alone or in combina-
tion with clinical measures [72], advanced sMRI techniques
for AD now include the use of automated regional assess-
ments of cortical thickness, loss of basal forebrain cholin-
ergic neuronal populations [73], and analyses of alterations
in structural connectivity. Although the former two methods
provide a step beyond the sMRI determination of HA, the
latter offers a look at consequences of early neuronal loss
and alterations in white matter connectivity through the
use of diffusion tensor imaging (DTI) and tractography
[74–76]. Investigations using DTI-based methods have pro-
vided consensus that early white matter changes in MCI and
AD affect the uncinate fasciculus, cingulum, and corpus cal-
losum. Together with advances in functional MRI (fMRI;
see the following), DTI-based white matter assessments pro-
vide increasing anatomic correlates to clinical complaints
and subsequent physiologic alterations assessed via fMRI.
Additional improvements in these techniques are required.
Unfortunately, current sMRI methods continue to be
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results [77–79]. Novel protocols are being developed to
improve the reliability of results and include diffusion
kurtosis imaging [80], diffusion spectrum imaging [81],
anomalous diffusion imaging [82], higher-order tensor
modeling [83], and compartment modeling [84]. Most as-
sessments using sMRI technologies and methods have
been used to compare normal subjects with those clinically
defined as having either prodromal or actual AD in cross-
sectional studies. In an effort to improve diagnostic accuracy
of sMRI in the future, investigations will require serial as-
sessments of disease progression in at-risk subjects, to better
define clinically relevant anatomic variations. In addition, as
novel sMRI methods become more widely available and
tested under clinical conditions, their potential utility in
defining preclinical AD may be realized.
3.2.2. Functional MRI
fMRI is used to assess the physiological status of the
resting brain state and complex neural responses to tasks.
Resting-state fMRI has featured the analysis of spontaneous
intrinsic brain activity under basal conditions (without stim-
ulation or task-based activity), typically depicted as altered
states of blood oxygen level–dependent signals [50], and
provides insight into the functional capability of resting state
networks, known as the default-mode network (DMN) [85].
AD features a disrupted DMN, probably resulting from the
evolving pathologic anatomy of disease progression. These
explicit DMN deviations have been suggested as biomarkers
for AD [86,87]. In addition, dorsal and ventral activation
networks have been defined and monitored for specific
deviations related to the dementing process, in addition to
DMNs [50], allowing assessment of a variety of intercon-
nected brain regions. The use of episodic memory tasks on
subjects undergoing fMRI allows visualization of hippocam-
pal and medial temporal lobe memory-related activation and
is thought to represent a physiologic correlate to information
encoding. With the memory-associated deficits seen with
prodromal and actual AD, task-based methods are gaining
momentum in AD research. Decreased activation within
the medial temporal lobe has been noted in MCI patients un-
dergoing such task-based memory testing [88,89]. As can be
seen in Table 2, monitoring any of these individual networks
provides variable but potentially significant sensitivity and
specificity in discriminating between preclinical and clini-
cally manifest subjects. Further investigations and imaging
protocol modifications will probably be required to limit
variability of results using these techniques and for investi-
gating the combined use of fMRI with other clinical and
biomarker modalities to improve accuracy in defining the
preclinical state of AD.
3.2.3. Positron emission tomography
For decades [90], PET imaging has provided focal differ-
ences in fluorine 18 fluorodeoxyglucose (18FDG) allocation
to provide rates of regional cerebral metabolic rate (rCMR)activity through glucose utilization and, thereby, helping
define physiological brain changes seen as part of the normal
aging process or a dementing condition. A recent review [91]
has assessed the pertinent post-2000 literature related to
diagnostic accuracy of 18FDG PET in AD studies, primarily
with clinically defined diagnoses in cross-sectional studies,
but also in longitudinal investigations and those with patho-
logic correlations. These reviewed studies have been sum-
marized in Table 2 and indicate variable sensitivity and
specificity for modern 18FDG PET methods. The differenti-
ation between AD and FTD is where 18FDG PET is gaining
significant clinical utility [92].
Amyloid plaque pathology is frequently found in brains
of individuals without clinical or pathologic evidence of
AD. Amyloid PET imaging using the carbon 11–labeled
Pittsburgh compound B (11C-PiB) has found a similar inci-
dence of amyloid binding in comparable subjects [93,94].
Although PET ligands labeled with 18F have a half-life of
110 minutes, allowing production and distribution from a
nearby cyclotron facility, early amyloid PET imaging with
11C-PiB was limited to centers having their own cyclotron,
radiochemistry, and pharmaceutical capabilities because of
a half-life approaching 20 minutes. The Food and Drug
Administration approved 18F-florbetapir in 2012, a fluori-
nated ligand, opening the possibility of more widespread
use of amyloid imaging options in clinical centers. Addi-
tional 18F amyloid-binding compounds continue to be devel-
oped, including flutemetamol, florbetaben, and AZD4694.
Although these 18F compounds have shown some problem-
atic nonspecific white matter binding, except the latter [95],
they all show similar amyloid binding results to 11C-PiB
when correlated to pre- and postmortem analyses [93,96].
Risk of using these ligands is extremely low, especially in
the dementia population age groups.
Information related to in vivo amyloid plaque presence in
elderly subjects remains to be adequately correlated with
preclinical (asymptomatic) stages of AD and those at risk
for phenoconversion. Some cognitively normal seniors
show increased 11C-PiB binding compared with other nor-
mals in their age group. In most cognitively normal subjects,
11C-PiB binding increases from less than 10%, below the age
of 70 years, up to 40% in those aged 80 years [97]. As noted
in Table 2, PET amyloid radioligands provide significant
single-method sensitivity and specificity in differentiating
between those with AD and NCs, as well as other conditions.
3.2.4. Single-photon emission computed tomography
SPECT imaging methods have typically used technetium
99m compounds to assess regional cerebral blood flow
(rCBF), with alterations in perfusion noted in various de-
menting conditions [98]. With rCBF tightly coupled to
rCMR, many investigations have shown the close correlation
between SPECTand PET in relation to regional assessments.
Although this physiologic linkage is indeed present, SPECT
images suffer from a lack of spatial resolution compared
with PET images. These resolution performance differences
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when comparing SPECT with PET diagnostic accuracy
(see Table 2). Although the major additional advantage of
SPECT over PET had previously been related to cost differ-
ences and availability, the advent of 18F compounds is allow-
ing a greater number of PET imaging facilities to be justified
and bringing down their imaging costs toward levels that
compete with SPECT.
Differentiation of various dementing conditions with
SPECT imaging (see Table 2) has been reported useful but
typically with less accuracy than with PET imaging modal-
ities. The advent of improved image analytics for both PET
and SPECT make obvious discrepancies between the modal-
ities more difficult to discern. Ultimately, the visual resolution
provided might be the deciding factor as to whether PET or
SPECT is selected by investigators for use in their analyses.
3.2.5. Magnetic resonance spectroscopy
Proton magnetic resonance spectroscopy (1H-MRS) is a
neuroimaging method that allows sampling and measurement
of a variety of different brain metabolites in a single session.
Each metabolite has the ability to provide information that is
sensitive to pathologic changes at the cellular and evenmolec-
ular levels. Typically monitored metabolites include N-acety-
laspartate (NAA), myoinositol (mI), and choline (Cho), with
creatine (Cr) typically used as an internal reference standard.
Quantitative measures are often presented as ratios with the
internal standard or other metabolites (e.g., NAA/Cr, NAA/
mI, mI/Cr, Cho/Cr). NAA’s intraneuronal localization allows
its 1H-MRS signature to represent neuronal density and/or
viability. Generation of NAA is thought to occur within mito-
chondria [99], so it has also been used as a marker of mito-
chondrial integrity and function. In contrast, most brain mI
is within glial cells [100], and increased levels have been
correlated with glial proliferation responses in inflammation
or gliosis [101,102].
Voxel volumes determine the regions of interest, within
which metabolite signals are quantified. The larger the voxel
volumes used, the greater the partial volume averaging seen
with the surrounding tissues. With greater partial volume
averaging, there is reduced localization specificity and
metabolite signals. The smaller voxel volumes (8 cm3)
used in 1H-MRS to reduce partial volumetric effects require
higher signal-to-noise ratios (SNRs), which can be
augmented by increasing magnetic field strength (Tesla or
T). With 1H-MRS, field strength is a major determinant of
SNR and, therefore, of the quality of the data obtained.
Three-Tesla scanners, for example, provide SNRs at smaller
voxel volumes than associated comparable SNRs in 1.5-T
scanners. High-resolution spectroscopic methods combined
with improved sMRI resolutions may ultimately provide a
metabolic imaging method [103].
Ratios of NAA to mI are reduced in parietal cortex of AD
subjects compared with frontal cortex [104], corresponding
to previously reported regional neuropathologic differences
[35]. Table 2 depicts findings from 1H-MRS studiescomparing clinical AD to NC subjects and from genetically
defined preclinical EOAD subjects and controls not
harboring the dominant mutation associated with EOAD.
The LOAD review [66] investigates findings from subjects
with either AD or normal cognition, defined on a clinical ba-
sis. The five investigations assessed a total of 150 AD sub-
jects and 138 controls in cross-sectional studies.
Calculated 1H-MRS mean sensitivity and specificity for
these combined groups were 78.8 and 84.8, respectively, in
differentiating those with AD from controls, and with the
sensitivity and specificity ranges depicted in Table 2. As
has been previously noted with other biomarkers, combining
1H-MRS with other biomarkers increases diagnostic
accuracy.
The EOAD study [67] summarized in Table 2 is of partic-
ular interest to the discussion of preclinical biomarkers in
this review because 1H-MRS is used to differentiate known
at-risk subjects, harboring an autosomal dominant and fully
penetrant presenilin-1 gene mutation, from subjects without
this mutation. In comparing these two distinct groups, brain
metabolite differences in the posterior cingulate and precu-
neus appeared to be optimally sensitive and specific in pre-
dicting those harboring the mutation from those who did
not. Similar investigations in LOAD patients will await the
development of an accurate preclinical biomarker of even-
tual clinical disease.3.3. Peripheral blood
Currently, there is a paucity of easily executed inexpen-
sive methods that provide reliable biomarkers able to predict
the at-risk phenotype of AD, despite the previously
described and commonly used CSF and neuroimaging mo-
dalities. New techniques are required to provide novel
insight and means to support preventive strategies during
the asymptomatic stages of AD. Individuals selected via
these methods could then be placed on therapeutic regimens
that may alter disease trajectory [105]. Biomarkers that have
been characterized using CSF and neuroimaging are highly
accurate, but they remain difficult to generalize into clinical
practice because of the invasive nature of the former and
cost-prohibitive technology associated with the latter. By
definition, a biomarker should expedite early detection and
diagnosis with high degree of accuracy, should be cost-
effective, and easily translated to general use [106]. In recent
years, there has been a paradigm shift toward interrogating
peripheral blood because it is accessible by minimally inva-
sivemeans, offers a relatively inexpensive substrate for anal-
ysis, and provides biosignatures that may be predictive,
diagnostic, and prognostic for AD and other neurologic dis-
eases [107,108].
3.3.1. Issues with brain biomarkers in the blood
Historically, the sensitivity and specificity of blood bio-
markers have been lower than those from CSF. Reasons for
this include the fact that the concentration of the CNS analytes
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the brain owing to the blood-brain barrier (BBB), challenging
the ability of analytical methods to identify CNS-specific
signals of illness. Results frommost studies reporting putative
blood biomarkers for AD have been difficult to reproduce and
validate with adequate specificity and sensitivity. There is a
growing body of evidence, however, that preclinical AD
may have a biosignature that can be deduced from peripheral
blood (see Table 3) [109–116]. For example, Kiddle et al.
[114] replicated blood-based proteomic biomarkers of AD
for a total of 163 candidate entities reported by 21 different
discovery-based studies. Using the SOMAscan proteomics
technology (SomaLogic, Inc, Boulder, CO, USA), they
were able to replicate 94 proteins. Nine of these proteins
were directly related to the AD phenotype [114]. Although
more validation studies with heterogeneous populations
are needed to further refine the biomarker panel, these find-
ings suggest consistent alteration of the blood proteome in
AD patients.
Blood comprises a liquid component (serum or plasma)
and different types of cells, including the mononuclear leu-
kocytes, which contain the deoxyribonucleic acid (DNA)
and ribonucleic acid (RNA), erythrocytes, and platelets.
Each blood component has its advantages for delineation
of different biomarker species. The serum and plasma can
be effectively used to identify proteins and small molecule
metabolites or lipid profiles. These same biomarkers can
also be used for following disease progression or response
to treatment. RNA can be obtained from leukocytes but is
also present in the plasma (or serum) exosomes and, hence,
represents a unique opportunity for biomarker discovery and
development. With the advent of newer and sophisticated
technological platforms, there has been an aggressive effort
toward developing bioinformatics tools for analyses of high
throughput and high dimensional “omics” approaches to
build classifier models that predict different physiological
states. Another aim of bioinformatics is also to integrate
different “omics” data using computational modeling ap-
proaches [117]. A potential issue, however, is the variability
in results depending on the statistical or computationalTable 3
Accuracy of blood-based biomarkers in selected AD studies
Name of biomarker (groups) Method used
Panel of 18 proteins (AD vs. NC) Antibody array
Plasma clusterin (AD vs. NC) LC-MS/MS
Panel of 25 proteins (AD vs. NC) Immunoassay
Aclarus Dx (AD vs. NC) Transcriptomics
Desmosterol (AD vs. NC) LC-MS
Panel of 9 proteins (AD vs. NC) SOMAscan proteomic assay
miRNA 125-b (AD vs. NC) miRNA profiling
12 miRNA signature (AD vs. NC) miRNA profiling
Abbreviations: AD, Alzheimer’s disease; Spec %, specificity (%); Sens %, se
chromatography-tandem mass spectrometry; LC-MS, liquid chromatography-ma
the curve; FDR, false discovery rate; miRNA, micro–ribonucleic acid.
NOTE. “Other” indicates additional accuracy measure presented. Aclarus Dx imethods used to identify these biomarkers. It is now believed
that the use of univariate methods to delineate blood bio-
markers is not sufficiently sensitive or specific for the diag-
nosis of complex, multifactorial, and heterogeneous
physiologies as AD. To circumvent these limitations, devel-
opment of “biomarker panels” assessing multiple molecular
entities is likely to yield higher consistency and accuracy.
Finally, lack of standardization of procedures for blood
collection, processing, and storage leads to preanalytical
variability causing inconsistencies in downstream analysis
and results [118]. Preanalytical variables include incubation
times before separating plasma (or serum) from cells, type of
blood collection tubes, temperature for collection and stor-
age [119], time in storage, and the number of subsequent
freeze-thaw cycles. Thus, the availability and use of standard
protocols is imperative to ensure cross-platform and interla-
boratory reproducibility [120–122].
3.3.2. Novel blood-based biomarkers for AD
Despite these challenges, a concerted effort toward iden-
tification and validation of blood-based biomarkers of AD
using a wide array of technological platforms is available
today. For example, circulating microRNAs, as biomarkers
of AD, are gaining credence as more research efforts are
made in this direction [115,116,123–125]. A blood-based
validated transcriptomic signature was recently reported
with a specificity of 67.1% and a sensitivity of 81.3%
[112]. Whole transcriptome sequencing (RNAseq) technol-
ogy is a promising next-generation approach that has advan-
tages for the identification of blood biomarkers of AD.
Specifically, RNAseq offers high efficiency, broad dynamic
range, and deep scope of detection [126].
A number of independent studies have focused on
discerning blood-based proteomic biomarkers of AD. Blood
represents a rich mixture of molecules for biomarker discov-
ery for risk and disease stratification. Blood affords measure-
ments of proteins over a broad dynamic range, featuring
multiple isoforms and splice variants, as well as entities re-
sulting from different posttranslational modifications. More-
over, because serum and plasma contain high amounts ofReported biomarker accuracy
(Sens %/Spec %/Other) Reference
NA/NA/accuracyw90% [109]
NA/NA/P 5 .05, not effective alone [110]
80/91/ROC AUC 5 0.91 [111]
81.3/67.1/NA [112]
NA/NA/ROC AUC 5 0.8 [113]
NA/NA/FDR q values ,0.1 [114]
80.8/68.3/NA [115]
92/95/accuracy 93% [116]
nsitivity (%); NC, normal control; NA, not available; LC-MS/MS, liquid
ss spectrometry; ROC, receiver operating characteristic; AUC, area under
s manufactured by the Diaxonhit Group, Paris, France.
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biomarker discovery requires enrichment techniques for
low abundance proteins and sensitive technological plat-
forms to facilitate detection and quantification of protein
biomarkers. Mass spectrometry (MS) has emerged as the
most popular platform for candidate biomarker develop-
ment. Several studies have used two-dimensional electro-
phoresis in combination with MS for identification of
protein biomarkers [127,128]. Ray et al. [109] have reported
a panel of 18 signaling proteins in plasma capable of predict-
ing AD with 90% accuracy, although these studies have not
been replicated. Lundstrom et al. [129] have provided a
novel plasma glycan signature to discriminate NC subjects
from those with MCI and AD, with a sensitivity of 89.3%
and a specificity of 79.1%. Recent technological advance-
ments in analytical technologies such as nuclear magnetic
resonance and ultra-performance liquid chromatography or
gas chromatography coupled with high-resolution tandem
MS have enabled accurate detection and quantitation of
small-molecule metabolites for which high throughput, rela-
tively inexpensive, clinical assays can be developed to facil-
itate early detection, while also providing prognostic
information and monitoring capabilities. Additionally, iden-
tification of dysregulated pathways in AD is likely to facili-
tate the development of novel therapeutics. Several
metabolomic studies in the recent years have focused on
serum and plasma profiling using targeted and untargeted
approaches. A recent combined cross-sectional and longitu-
dinal study identified a panel of 18 plasma proteins (cyto-
kines, chemokines, growth factors, and binding proteins),
which discriminated symptomatic AD from cognitively
NC subjects with nearly 90% accuracy and predicted conver-
sion from symptomatic MCI to AD with 91% accuracy
[109]. Unfortunately, several subsequent studies using this
profile failed to replicate the accuracy of conversion from
MCI to AD reporting lower accuracies of 60% to 70%
[130,131]. Another promising cross-sectional study reported
a panel of 18 biomarker species, many related to inflamma-
tion, which correctly classified symptomatic AD from
cognitively NC subjects with a sensitivity and specificity
of 85% and an area under the curve (AUC) of 93% [132].
A reduced panel of eight metabolites including cortisol and
pancreatic polypeptide showed a sensitivity and specificity
of correct classification of 83%. The biomarker panel was
validated in an independent cohort of healthy controls and
symptomatic AD from the Alzheimer’s Disease Neuroimag-
ing Initiative sample set and provided sensitivity and speci-
ficity of 80% with an AUC of 85%. Sato et al. [113] have
reported a decrease in plasma desmosterol levels in AD pa-
tients compared with control subjects and a significant
decrease in desmosterol/cholesterol levels. Another study re-
ported a decrease in plasma levels of lysophospholipid 18:1
of AD patients, which correlated with severity of the disease
[113]. Trushina et al. have conveyed a ultra performance
liquid chromatography-time of flight-mass spectrometry
(UPLC-TOF-MS)–based identification of a multimetabolitepanel that includes the amino acid phenylalanine, lysine,
leucine, serotonin, cholesterol, and phospholipids that could
discriminate between NC and individuals with MCI
[133–135], whereas Han et al. [136] reported differences in
plasma ceramide levels as a potent discriminator of AD.
The Framingham Heart Study, meanwhile, disclosed a
decrease in phosphatidylcholine (PC) levels of AD patients
[137]. Studies have shown deficits in brain structural glycer-
ophospholipids and sphingolipids, as well as alterations in
metabolites of these complex structural lipids, which act as
signaling molecules [138]. These alterations may well be re-
flected in blood profiles and hence are an interesting class of
metabolites to pursue as biomarkers of AD. In summary,
there has been a concerted research effort toward the devel-
opment of biomarker panels using blood as a discrimination
matrix. More longitudinal and cross-validation studies with
larger andmore diverse ethnic cohorts, however, are required
to develop biomarker panels that could be used effectively in
the clinic in conjunction with the current testing methods.4. Novel methods to define preclinical fluid-based
biomarkers for AD
As noted in the CSF and blood-based biomarker sections,
novel approaches using biofluids include the use of specific
p-tau isoforms to determine disease stage and a variety of
specific “omic” analyses for blood components (see
Table 3). Blood appears to offer a distinctly rich environment
compared with CSF for collecting novel information
regarding ongoing disruptions in pathobiologic networks.
The lack of significant cellular components within CSF
limits the ability to access DNA and RNA for investigations
and primarily focuses on assays using metabolomic or pro-
teomic methods for differentiation. In contrast, peripheral
blood’s cellular and liquid components provide a rich source
of both genetic materials for interrogation in addition to pro-
teomic and metabolomic species.
The major advantage offered by CSF over blood is the
unique direct contact that the former has with the CNS envi-
ronment, whereas the latter’s interactions are indirect and
limited by the BBB. These facts, related to compartmentaliza-
tion of assayable analytes, have made it difficult for some to
accept blood-derived findings as germane to AD-related pro-
cesses within the CNS because of the apparently small flux
of putative biomarkers from theCNS to peripheral blood. It re-
mains vital to understand the communication between these
two compartments and discern the implications for disease
detection and progression. Although many CNS metabolites
or other entities are not in established steady-state relation-
ships with blood, injury to or disease within the CNS clearly
drives a temporal evolution of peripherally detectable signa-
tures [139]. A recent abstract presented at the Sixth Annual
Clinical Trials on Alzheimer’s Disease Conference [140],
and subsequent manuscript publication [141], underscores
the potential for such observations and correlations in a longi-
tudinal study assessing preclinical and clinical AD.
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specific plasma lipid species (Fig. 3) present in cognitively
normal subjects who phenoconvert to either amnestic MCI
(aMCI) or AD within 2 to 3 years compared with those
remaining cognitively intact [141]. The panel of plasma lipids
discovered was validated in an independent group of subjects
within the same study cohort, with greater than 90%
sensitivity and 90% specificity. Although the identified lipid
species are not currently known to freely equilibrate between
the blood and CNS, reductions in certain plasma lipids [142]
and parenchymal brain lipids [143] have been previously
reported in MCI and AD. Although further validation of
these lipidomic findings is required, as well as application to
larger and more diverse populations, this investigation [141]
supports the use of peripheral blood for unbiased screening
to determine alterations in pathobiologic networks within
the CNS of preclinical AD patients that are reflected in the
periphery.Fig. 3. A representation of lipidomic results from the study of Mapstone et al. [141
seen, for each member of the lipidomic set, between cognitively normal subjects
convert to either amnestic MCI (aMCI) or Alzheimer’s disease (AD) (Converterp
are not to scale. The dotted line portrays the reduction in select lipid levels seen
of the 10 lipid species identified and validated using MS-based metabolomic analys
fromNC subjects. (C) Representation of receiver operating characteristic (ROC) cu
the 10–lipid biomarker panel. Area under the curve (AUC)5 0.96. (D) Representat
subjects using the 10–lipid biomarker panel. AUC5 0.92. The asterisk (*) in panel
acylcarnitine; PC, phosphatidylcholine; CI, confidence interval.5. Biomarker epidemiology, costs, and benefits
With the increasing pressure to develop accurate bio-
markers of preclinical AD, many have started to examine
the costs and benefits associated with the various bio-
signatures. Ultimately, these analyses will be germane to
the overall cost of care for AD-afflicted individuals. The
costs are not insignificant for accessing various biomarkers
discussed in this review (see Table 4). What is clearly noted,
however, is the increased risk associated with obtaining CSF
for biomarker analysis compared with both neuroimaging
and blood-based methods. Additionally, there is a major
cost differential between obtaining blood for biomarker
analysis versus both CSF and neuroimaging methods. Based
on available information, calculated costs for blood collec-
tion for biomarker analysis are less than 10% the cost of
obtaining biomarkers via CSF or neuroimaging. As noted
earlier in the discussion of diagnostic accuracy of each of]. (A) Schematic depiction of the relative quantitative lipidomic differences
who remain normal (NC), those cognitively unimpaired destined to pheno-
re), and those with presenting with aMCI or AD (aMCI/AD). The box sizes
with Converterpre subjects compared with NC and aMCI/AD. (B) The list
es that accurately differentiate between cognitively unimpaired Converterpre
rve analysis of Converterpre versus NC for the discovery set of subjects using
ion of ROC curve analysis of Converterpre versus NC for the validation set of
B indicates P, .005, whereas for all other analytes in panel B, P .05. AC,
Table 4
Alzheimer’s disease biomarker costs*
Biomarker method Patient discomfort Risk Est. cost per 1000 subjects Additional considerations
Cerebrospinal fluid Significant Moderate to high $350,000 to .$1,000,000 Risks include significant headache (in 40%),
back or leg pain (in 11%), and rare
meningitis, epidural abscess, or subdural
hematoma. Requisite: skill of staff
performing procedure.
Neuroimaging Mild to moderate Low Claustrophobia, need for lying still for
long periods of time, expensive facility
and imaging equipment, specialized staff,
significant time for post hoc analysis, and
variability between facilities
sMRI $400,000 to .$800,000
fMRI $600,000 to .$900,000
PET $1,000,000 to $2,000,000
SPECT $1,000,000 to $2,000,000
MRS $700,000 to $1,000,000
Blood based Minimal Low $40,000 to $100,000 Possible bruising at the site of venipuncture,
and vasovagal reaction
Abbreviations: Est., estimated; sMRI, structural magnetic resonance imaging; fMRI, functional magnetic resonance imaging; PET, positron emission tomog-
raphy; SPECT, single-photon emission computed tomography; MRS, magnetic resonance spectroscopy.
*Cost calculations based on available online information regarding estimated individual testing charges. These are procedural charges only and do not include
the costs of assays performed using cerebrospinal fluid or blood-based analyses or the personnel charges for time spent in association with imaging or fluid-based
bioinformatic analyses.
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support CSF and neuroimaging biomarker results over
blood-based methods. Most of these cited studies have
been cross-sectional in nature, comparing clinically normal
subjects with those having clinical AD (either MCI or AD).
If additional investigations using blood-based biomarkers
provide comparable or greater diagnostic accuracy than
CSF and neuroimaging modalities, there is no question
about which will become the preferred screening method
in preclinical investigations and perhaps subsequently in
clinical practice. Because of the minimally-invasive nature,
low risk, and low cost to access blood for biomarker analyses
(see Table 4), asymptomatic subjects and their physicians
will have fewer issues moving forward with diagnostic
screening. This development of preclinical data will be
important in further definition of the underlying pathobio-
logic networks that characterize high-risk individuals, and
through analysis of network nodes, additional targets
for therapeutic development will emerge. This financial
calculus suggests that biomarker modalities applicable
to screening large populations of preclinical subjects require
low costs and high accuracy. It is through systematic
application of these methods that investigations are expected
to yield clinical prescription of disease-modifying
therapeutics.
What is much more difficult to estimate is the impor-
tance of refinements in study design and biomarker spec-
imen/data handling in future investigations. The ability to
compare different study results is predicated on uniform
application of reliable clinical instruments to assess cogni-
tive and other functions. In the clinical AD research field,
there is a need for further consensus on the optimal clinical
approach for cognitive assessments that will yield consis-
tency among individuals from different studies. In addition,
the rigorous collection and processing of CSF and blood
for biosignature measurements must be standardized tominimize technical and biologic variance that is unrelated
to disease or at-risk status.6. Conclusions
After the initial success of CSF biomarkers in defining
differences between symptomatic AD subjects from
asymptomatic controls, the biomarker momentum has
shifted toward minimally invasive modalities to define
the preclinical stages. Advances in neuroimaging, with
the attendant low risk associated with these investigations
and significant accuracy, have indicated the validity of
preclinical biomarkers for AD. Although the definition
of differences between manifest disease and normals has
been an important early step in the genesis of these bio-
signatures, longitudinal investigations of subjects at risk,
who subsequently phenoconvert to clinical AD, will be
required for an improved definition of the preclinical
phenotype. Blood-based biomarkers may offer such a po-
tential in screening asymptomatic subjects while
providing significant insight into the ongoing pathobi-
ology. Once the at-risk preclinical AD group is defined
using this relatively inexpensive low-risk solution, the
addition of other biomarker methods to further refine
the understanding of the operational network aberrations
may be considered. A clear definition of the preclinical
phenotype, however, is necessary in leading to eventual
secondary prevention trials and the potential to modify
the course of AD.Acknowledgments
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